<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical presentation and diagnosis of inflammatory bowel disease in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical presentation and diagnosis of inflammatory bowel disease in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical presentation and diagnosis of inflammatory bowel disease in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Leslie M Higuchi, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Athos Bousvaros, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melvin B Heyman, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn disease (CD). UC affects the colon and is characterized by inflammation of the mucosal layer. CD can involve any component of the gastrointestinal tract from the oral cavity to the anus and is characterized by transmural inflammation. These disorders have distinct pathologic and clinical characteristics, but their pathogenesis remains poorly understood. The diseases may present at any age, but peak incidence is in adolescents and young adults. (See
         <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">
          "Definitions, epidemiology, and risk factors for inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">
          "Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         The diagnostic evaluation of IBD involves five steps. The first two typically are performed by the general pediatrician, while the last three are performed by the pediatric gastroenterologist.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical suspicion of the illness based upon clinical symptoms, examination, and screening laboratory data
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of other illnesses that have a similar presentation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Differentiation between CD and UC
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localization of the region of the disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identification of extraintestinal manifestations (eg, sclerosing cholangitis)
        </p>
        <p>
        </p>
        <p>
         Patients with very early-onset IBD (ie, under age six years, and especially those under age two years) may also warrant immunologic evaluation and genetic sequencing for monogenic forms of IBD.
        </p>
        <p>
         The diagnosis of IBD in children is reviewed here. Other topics that discuss IBD in children are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">
          "Overview of the management of Crohn disease in children and adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">
          "Management of the hospitalized child or adolescent with acute severe ulcerative colitis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2640068188">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The peak incidence of IBD occurs in patients between the ages of 15 and 30 years [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 5 to 10 percent of patients develop their IBD during childhood or adolescence, although the incidence of pediatric IBD appears to be increasing [
         <a href="#rid2">
          2-4
         </a>
         ]. CD and UC are rare under the age of five years but have been reported as early as infancy [
         <a href="#rid5">
          5-9
         </a>
         ]. In Canada, a country with a high incidence of IBD, the incidence is 10 to 20 individuals per 100,000 population in children 10 to 20 years, compared with approximately 2 per 100,000 in those younger than 10 years [
         <a href="#rid10">
          10
         </a>
         ]. Over 50,000 children in the United States have IBD [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Very early-onset inflammatory bowel disease'
         </a>
         below.)
        </p>
        <p>
         Compared with adults, children with IBD are more likely to present with extensive intestinal involvement and have rapid clinical progression [
         <a href="#rid11">
          11,12
         </a>
         ]. Children also are more likely to have a family history of IBD, suggesting a stronger genetic association for IBD presenting during childhood [
         <a href="#rid5">
          5,13
         </a>
         ]. In particular, a small subset of children who develop IBD-like intestinal inflammation before six years of age have a single gene defect that affects immune function or disturbs epithelial barrier function, collectively known as "monogenic IBD" [
         <a href="#rid6">
          6,9,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4062.html" rel="external">
          "Genetic factors in inflammatory bowel disease"
         </a>
         and
         <a class="local">
          'Very early-onset inflammatory bowel disease'
         </a>
         below.)
        </p>
        <p>
         Data from a multicenter pediatric IBD registry provide a description of the characteristics of pediatric IBD according to age [
         <a href="#rid5">
          5
         </a>
         ]. The following observations were made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mean age at diagnosis was 10.3 years; 15 percent of patients were diagnosed before age six years (6 percent before three years), 48 percent at 6 to 12 years, and 37 percent at 13 to 17 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history (including both first-degree relatives and extended family) was positive for IBD in 29 percent of patients overall and 44 percent of children with UC who were younger than three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated colonic disease, whether CD, UC, or indeterminate colitis, was more common among children younger than eight years than among older children.
        </p>
        <p>
        </p>
        <p>
         Other aspects of the epidemiology of IBD, including demographics, geographic and time trends, and risk factors, are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">
          "Definitions, epidemiology, and risk factors for inflammatory bowel disease", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H184210419">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3040381553">
         <span class="h2">
          Typical presenting symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IBD typically present in late childhood or adolescence with one or several of the following features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal symptoms – Diarrhea, bloody stools, abdominal pain, or tenesmus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth – Growth failure (subnormal gains in height or weight, or weight loss), and/or delayed puberty. Growth failure is a common feature, especially in those with Crohn disease (CD). Nonetheless, a substantial number of children are overweight when they present with IBD because overweight and obesity are common in most populations [
         <a href="#rid15">
          15,16
         </a>
         ]. Thus, obesity or lack of growth failure should not preclude a diagnosis of IBD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical findings – Abdominal tenderness and/or mass (especially in the right lower quadrant), perianal disease (fistulae, anal skin tags, or fissures  (
         <a class="graphic graphic_picture graphicRef121947" href="/z/d/graphic/121947.html" rel="external">
          picture 1
         </a>
         )), or occult blood in stool.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic symptoms – Fever and fatigue are common at presentation and during flares of disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extraintestinal manifestations – Oral ulcerations (eg, aphthous stomatitis)  (
         <a class="graphic graphic_picture graphicRef138273" href="/z/d/graphic/138273.html" rel="external">
          picture 2
         </a>
         ), clubbing, rash (erythema nodosum or pyoderma gangrenosum), eye inflammation (uveitis), jaundice or hepatomegaly, or arthritis. (See
         <a class="local">
          'Extraintestinal manifestations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Findings suggesting colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colitis (inflammation of the large intestine) can occur in patients with either UC or CD. Colitis usually presents as a subacute illness characterized by diarrhea that almost always contains blood, fatigue, anemia, and sometimes weight loss. The onset of symptoms may be insidious, with diarrhea that is initially nonbloody and sometimes poor weight gain. Some children have a more fulminant presentation, with severe abdominal pain, frankly bloody diarrhea, tenesmus, fever, leukocytosis, and hypoalbuminemia.
        </p>
        <p>
         By definition, patients with UC have colitis that affects the rectum and extends proximally to a variable degree. CD also may involve the colon, either exclusively (Crohn colitis) or in combination with small intestinal involvement (Crohn ileocolitis). Individuals with IBD presenting at a young age are particularly likely to present with symptoms of colitis: 10 to 15 percent of children and adolescents with IBD present prior to six years of age, and the majority of these children have isolated colonic disease (either UC or Crohn colitis) [
         <a href="#rid5">
          5,17,18
         </a>
         ]. CD tends to be diagnosed in late childhood or adolescence and is the predominant form of IBD diagnosed after eight years of age [
         <a href="#rid5">
          5,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Other gastrointestinal manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients, particularly those with CD, present with nonspecific gastrointestinal symptoms that may be difficult to distinguish from more common conditions such as functional abdominal pain. The most useful indicators of possible IBD in a child with abdominal pain are: diarrhea, growth failure, pubertal delay, weight loss, rectal bleeding, pallor/fatigue, perianal skin tags  (
         <a class="graphic graphic_picture graphicRef121947" href="/z/d/graphic/121947.html" rel="external">
          picture 1
         </a>
         ) (which may be misdiagnosed as hemorrhoids), perianal fistulae or abscesses, a palpable abdominal mass, and a family history of IBD. The abdominal pain associated with CD is often focal and located in the right lower quadrant. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11172431">
         <span class="h2">
          Growth failure or delay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth failure or growth delay is common at presentation, particularly in children with CD. The earliest and most subtle form of growth failure is a decrease in height velocity; this may progress to short stature for age, delayed bone age, and/or pubertal delay. Up to 50 percent of patients with CD have a decrease in height velocity before the onset of any other intestinal symptoms [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1351752">
         <span class="h2">
          Extraintestinal manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extraintestinal conditions associated with IBD (including nonspecific symptoms such as arthralgias) are identified in approximately 10 percent of patients at presentation and up to 30 percent of patients within the first few years after the IBD is diagnosed [
         <a href="#rid21">
          21,22
         </a>
         ]. These may involve the mouth  (
         <a class="graphic graphic_picture graphicRef138273" href="/z/d/graphic/138273.html" rel="external">
          picture 2
         </a>
         ), skin, joints, liver, eye, and (rarely) other organs  (
         <a class="graphic graphic_table graphicRef81867 graphicRef88092" href="/z/d/graphic/81867.html" rel="external">
          table 1A-B
         </a>
         ).
        </p>
        <p>
         These disorders are idiosyncratic, appearing in some patients and not others with no clear pattern, although they are more often associated with colonic disease (ie, Crohn colitis or UC). Certain extraintestinal manifestations are more common in CD compared with UC, including oral aphthae (superficial ulcerations, also known as aphthous stomatitis), erythema nodosum, digital clubbing, and arthritis. They do not consistently correlate with the degree of intestinal inflammation. Occasionally, patients present with extraintestinal symptoms (such as aphthous stomatitis, arthritis, or liver disease) before any obvious gastrointestinal symptoms develop [
         <a href="#rid21">
          21,23
         </a>
         ].
        </p>
        <p>
         Details about these extraintestinal manifestations of IBD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Extraintestinal manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H184210643">
         <span class="h2">
          Laboratory features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following laboratory features are suggestive of IBD:
        </p>
        <p class="headingAnchor" id="H3941082656">
         <span class="h3">
          Blood tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia, increased white blood cell, and platelet count – Approximately 70 percent of patients have anemia at diagnosis of IBD (eg, hemoglobin level &lt;11 g/L) [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) – Approximately 65 to 75 percent of patients have an elevated ESR at diagnosis of IBD, and approximately 85 percent have elevated CRP [
         <a href="#rid24">
          24,26
         </a>
         ]. However, estimates vary depending on disease type (CD versus UC), disease severity, and on the cutoff value used to define abnormal ESR or CRP. There are no widely accepted cutoff values for ESR and CRP for identifying patients at risk for IBD, and the normal range for CRP varies among laboratories. In studies evaluating the predictive value of these inflammatory markers, an ESR &gt;20 or &gt;25 mm/hr and CRP &gt;5 or &gt;10 mg/L have been used [
         <a href="#rid26">
          26-28
         </a>
         ]. These markers are somewhat more sensitive for detecting CD than UC, and CRP is more sensitive than ESR [
         <a href="#rid29">
          29
         </a>
         ]. As an example, among children evaluated at a referral center for IBD, CRP was elevated in 100 percent of those with CD and 60 percent of those with UC [
         <a href="#rid26">
          26
         </a>
         ]. In the same study, ESR was elevated in 85 percent of patients with CD and 23 percent of those with UC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressed albumin level – Approximately 40 percent of patients with IBD have depressed albumin levels at diagnosis (eg, &lt;3.4 g/L) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Normal laboratory tests do not exclude the diagnosis of IBD. In a study of more than 500 children who ultimately were diagnosed with IBD, the ESR, hemoglobin, platelet count, and albumin level were all normal in 19 percent of children with UC and 9 percent of children with CD [
         <a href="#rid24">
          24
         </a>
         ]. Patients with more severe disease were more likely to have abnormal values on these laboratory tests, particularly the ESR. Thus, endoscopic and radiographic evaluation is sometimes appropriate in some patients in whom there is a strong clinical suspicion of IBD, even if initial blood tests are normal. (See
         <a class="local">
          'Endoscopy'
         </a>
         below and
         <a class="local">
          'Imaging'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4052321254">
         <span class="h3">
          Stool tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gross or occult blood
         </strong>
         – Bloody stool is a presenting feature in at least 80 percent of patients with UC and 40 percent of those with CD [
         <a href="#rid30">
          30,31
         </a>
         ]. If IBD is suspected but there is no history of gross rectal bleeding, a stool guaiac test may be useful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fecal calprotectin
         </strong>
         – Fecal calprotectin levels are elevated in inflammatory intestinal diseases and may be useful for distinguishing inflammatory gastrointestinal disease including IBD from noninflammatory causes of chronic diarrhea (such as functional abdominal pain) [
         <a href="#rid29">
          29,32
         </a>
         ]. However, the test characteristics vary depending on the prevalence of IBD in the study population. In settings with a high prevalence of IBD, such as a gastroenterology clinic, elevated fecal calprotectin (eg, &gt;200 mcg/g) is useful for identifying patients with a high likelihood of having IBD. In studies from referral centers for pediatric gastroenterology, fecal calprotectin had better performance characteristics for this purpose than ESR, CRP, or hypoalbuminemia [
         <a href="#rid33">
          33,34
         </a>
         ]. By contrast, in settings with a low prevalence of IBD, such as a primary care setting, fecal calprotectin is more useful to rule out IBD (ie, if fecal calprotectin is normal [eg, &lt;50 mcg/g], then IBD is unlikely) [
         <a href="#rid35">
          35-38
         </a>
         ]. Elevated levels of fecal calprotectin are also found in other causes of inflammatory diarrhea including bacterial and viral enteritis, intestinal lymphoma, celiac disease, food allergy, and immunodeficiency [
         <a href="#rid32">
          32
         </a>
         ], and also in the setting of juvenile polyps [
         <a href="#rid39">
          39
         </a>
         ]. Fecal lactoferrin also has been used as a marker for disease activity, but is less well-studied than fecal calprotectin [
         <a href="#rid40">
          40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">
          "Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'General laboratory tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fecal calprotectin levels are correlated with disease activity in both CD and UC [
         <a href="#rid42">
          42-45
         </a>
         ]. Therefore, this test can be useful in monitoring response to treatment, but because of limited sensitivity and specificity it should be used in conjunction with other laboratory tests and symptoms to arrive at clinical decisions. The potential benefits of this test also must be weighed against the cost and against the fact that it will not provide a definitive IBD diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fecal lactoferrin
         </strong>
         – Fecal lactoferrin has also been utilized to differentiate IBD from non-inflammatory gastrointestinal conditions. Studies have demonstrated comparable sensitivity and specificity to calprotectin. However, this biomarker is less commonly used clinically, perhaps because of fewer publications on its utility [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fecal leukocytes
         </strong>
         – Compared with fecal calprotectin and lactoferrin, fecal leukocytes have considerably lower specificity and sensitivity for detecting inflammatory diarrhea.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3403162906">
         <span class="h1">
          CANDIDATES FOR EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H2943089712">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         IBD should be suspected in a child presenting with one or more of the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bloody diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth failure (subnormal gains in height or weight, or weight loss) or pubertal delay
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic watery diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic abdominal pain, especially in the right lower quadrant
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perianal abscesses, fistulae, and fissures, oral ulcers, or arthritis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory abnormalities including anemia, elevated white blood cell and platelet count, elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), depressed albumin level, occult blood in the stool, elevated fecal calprotectin or leukocytes. (See
         <a class="local">
          'Laboratory features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H509333788">
         <span class="h2">
          When to refer
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest referral to a pediatric gastroenterologist as soon as IBD is strongly suspected based on marked clinical symptoms (eg, bloody diarrhea) and/or milder symptoms with laboratory abnormalities or a positive family history, as outlined above [
         <a href="#rid48">
          48
         </a>
         ]. Some of these steps may be performed by the general pediatrician, but a gastroenterologist is helpful for decision-making and performs the endoscopic evaluation, if indicated.
        </p>
        <p class="headingAnchor" id="H20369433">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of IBD is usually established by the combination of clinical features, with or without laboratory abnormalities, coupled with characteristic findings on imaging and endoscopy, including histopathologic analysis. Most patients with suspected IBD should be evaluated with each of the following steps  (
         <a class="graphic graphic_table graphicRef77827" href="/z/d/graphic/77827.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stool testing (see
         <a class="local">
          'Stool testing for enteric pathogens'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small bowel imaging (see
         <a class="local">
          'Imaging'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upper endoscopy and colonoscopy (see
         <a class="local">
          'Imaging'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         The order of evaluation depends on the type and severity of presenting features. Patients with isolated mild symptoms may not require completion of each of these steps but should be monitored. Depending on the dominant clinical symptoms, testing to exclude other conditions also may be required. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8243939">
         <span class="h2">
          Stool testing for enteric pathogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients presenting with diarrhea (especially bloody diarrhea) should be evaluated with a stool culture and tests for
         <em>
          C. difficile
         </em>
         toxin [
         <a href="#rid49">
          49
         </a>
         ]. Infection with an enteric pathogen can mimic IBD. However, they can also trigger IBD, so the presence of an enteric pathogen does not exclude the possibility of IBD [
         <a href="#rid50">
          50
         </a>
         ]. If enteric pathogens are identified, they should be treated. However, a positive result of
         <em>
          C. difficile
         </em>
         testing also may be due to colonization rather than infection in children with or without IBD, especially in younger children [
         <a href="#rid51">
          51
         </a>
         ]. Therefore, patients who fail to respond to treatment, or those with symptoms of IBD other than bloody diarrhea, including growth failure, should also be fully evaluated with endoscopy and imaging. If colonoscopy is performed, histopathologic features that suggest chronicity support the diagnosis of IBD rather than an infectious colitis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="local">
          'Features of ulcerative colitis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">
          "Diagnostic approach to diarrhea in children in resource-abundant settings", section on 'Laboratory testing and imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13111353">
         <span class="h2">
          Endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest both colonoscopy and upper endoscopy for patients with suspected IBD, even in the absence of clear lower gastrointestinal symptoms such as bloody diarrhea. The results help to exclude other causes of the symptoms, categorize the IBD as either ulcerative colitis (UC) or Crohn disease (CD)  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ), and document the disease activity and location to support therapeutic decisions [
         <a href="#rid30">
          30,49,52
         </a>
         ].
        </p>
        <p>
         The endoscopist should document the macroscopic findings and perform biopsies throughout the gastrointestinal tract to confirm the diagnosis through histopathology  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ). During colonoscopy, the terminal ileum should be examined if possible, and random biopsies should be taken from the terminal ileum and from each segment of the colon. The specimens should be labeled separately for histopathologic examination to document the location of microscopic abnormalities. (See
         <a class="local">
          'Differentiation between Crohn disease and ulcerative colitis'
         </a>
         below.)
        </p>
        <p>
         We and many other endoscopists prefer to perform endoscopy in children under anesthesiologist-administered
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         or general anesthesia. This approach improves patient comfort and increases the likelihood of a complete endoscopic examination. In a registry of children undergoing colonoscopy for a variety of indications, the short-term complication rate of the procedure was approximately 1 percent [
         <a href="#rid53">
          53
         </a>
         ]. Cardiopulmonary compromise associated with sedation and bleeding from polypectomy accounted for many of the complications in this series. According to this single study, the rate of complications was higher in patients who received intravenous sedation (1.7 percent) than in those who received anesthesia (0.8 percent).
        </p>
        <p class="headingAnchor" id="H13111361">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to endoscopy, imaging of the UGI tract (focused on the small intestine) is recommended, primarily to distinguish between UC and CD. This is because parts of the UGI tract, generally distal to the duodenum, are not accessible to the endoscope and because certain features of CD, such as stricturing and transmural inflammation, are better assessed by imaging techniques. Radiographic imaging of the small bowel is evolving. The relative advantages and disadvantages of each modality are outlined below [
         <a href="#rid54">
          54-56
         </a>
         ]. Additional information on imaging safety is available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.imagegently.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoZYdxzvQqx9VmbmqNcayEUKCjtXTC6Y5e9KALMc%2BCxiR&amp;TOPIC_ID=5879" target="_blank">
          Image Gently Alliance website
         </a>
         and in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">
          "Radiation-related risks of imaging"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnetic resonance enterography (MRE)
         </strong>
         – MRE is the preferred small bowel imaging modality in children, where available. The main advantage of this technique is avoidance of radiation exposure [
         <a href="#rid57">
          57
         </a>
         ]. Diagnostic performance of MRE for detection of active inflammation is high, with a sensitivity of 83 percent and a specificity of 93 percent [
         <a href="#rid58">
          58
         </a>
         ]. The technique also provides information about extraintestinal findings (eg, intraabdominal or perianal fistula or abscess, liver disorders, renal problems, and bone disease) [
         <a href="#rid59">
          59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MRE combines oral contrast distension of the bowel with intravenous administration of a gadolinium-based contrast material to detect mucosal bowel lesions and inflammatory activity  (
         <a class="graphic graphic_diagnosticimage graphicRef117821" href="/z/d/graphic/117821.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid62">
          62
         </a>
         ]. The patient is prepared with the oral administration of an osmotic agent, such as
         <a class="drug drug_pediatric" data-topicid="12715" href="/z/d/drug information/12715.html" rel="external">
          polyethylene glycol-electrolyte solution
         </a>
         (PEG) or mixture of dilute
         <a class="drug drug_pediatric" data-topicid="118048" href="/z/d/drug information/118048.html" rel="external">
          barium
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">
          sorbitol
         </a>
         (VoLumen, E-Z-EM) to distend the bowel.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This technique requires the patient to drink moderate amounts of contrast and cooperate with breath holding sequences. MRE is generally feasible in children as young as four to five years of age (with assistance of Child Life Services) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Computed tomography enterography (CTE)
         </strong>
         – CTE (CT of the abdomen with oral contrast) is a useful second-line option for small bowel imaging. It provides good visualization of the bowel lumen and bowel wall, as well as of extraintestinal complications such as abscess. Because CT can often be done more urgently compared with magnetic resonance imaging, it often is performed for patients with an acute concern, such as clinical suspicion of abscess [
         <a href="#rid64">
          64
         </a>
         ]. It is also useful for small children who cannot stay still for MRE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The main disadvantage of CTE is radiation exposure. A variety of methods can help minimize the radiation exposure [
         <a href="#rid65">
          65
         </a>
         ]; with use of these methods, CTE now has less radiation exposure than conventional fluoroscopy [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conventional fluoroscopy
         </strong>
         – Upper gastrointestinal series with small bowel follow-through (UGI/SBFT) traditionally has been used to evaluate the small bowel for suspected CD, but its use is decreasing [
         <a href="#rid30">
          30
         </a>
         ]. This modality provides good visualization of the small bowel lumen, revealing strictures and fistulas, but does not generally detect small ulcers or erosions and is less able to evaluate for transmural inflammation or abscess than MRE and CTE [
         <a href="#rid54">
          54
         </a>
         ]. It exposes the patient to a moderate amount of radiation, which can be minimized by using pediatric dose-minimizing protocols, such as reducing the number of images of the esophagus and stomach, and limiting imaging to the small intestine [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The relative merits of fistulography, CT, magnetic resonance imaging, and ultrasonography in evaluating anal fistulas are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2580.html" rel="external">
          "The role of imaging tests in the evaluation of anal abscesses and fistulas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23926440">
         <span class="h2">
          Other modalities
         </span>
        </p>
        <p class="headingAnchor" id="H726956503">
         <span class="h3">
          Video capsule endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Video capsule endoscopy (VCE) is increasingly used in adults for diagnosis and assessment of severity of CD [
         <a href="#rid69">
          69
         </a>
         ]. The role of this procedure in children with suspected IBD is evolving; it is approved by the US Food and Drug Administration for children older than two years [
         <a href="#rid70">
          70
         </a>
         ]. The technique has been effective in identifying small bowel involvement in IBD  (
         <a class="graphic graphic_picture graphicRef83589" href="/z/d/graphic/83589.html" rel="external">
          picture 3
         </a>
         ), which may be important for treatment decisions [
         <a href="#rid52">
          52,71-75
         </a>
         ]. In one study, VCE detected a greater extent of CD compared with UGI/SBFT and refined medical management for approximately one-half of the patients with known CD [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4072.html" rel="external">
          "Endoscopic diagnosis of inflammatory bowel disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2662.html" rel="external">
          "Wireless video capsule endoscopy"
         </a>
         .)
        </p>
        <p>
         It is unclear if the complication rate is higher in pediatric patients undergoing VCE compared with adults. In a series of 207 capsule endoscopies performed on pediatric patients (age range 8 to 21 years), the risk of symptomatic capsule retention was 5 percent among patients with known IBD (3 of 58 patients) and 38 percent among those with CD and known small bowel abnormalities (3 of 8 patients) [
         <a href="#rid71">
          71
         </a>
         ]. A meta-analysis that included the above study and 14 others reported capsule retention rates of 2.5 percent among patients with CD (9 of 359 procedures), which is similar to retention rates in adults with CD but somewhat higher than for children undergoing VCE for other indications [
         <a href="#rid77">
          77
         </a>
         ]. If small bowel imaging identifies areas of luminal narrowing that might result in a capsule getting stuck in the bowel, a patency capsule study should be performed prior to the VCE, as the passage of a patency capsule makes it less likely that the video capsule will be retained in the bowel [
         <a href="#rid75">
          75,78
         </a>
         ]. If a video capsule is retained in the small bowel, endoscopic or surgical removal of the capsule may be needed [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2442098432">
         <span class="h3">
          Ultrasonography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ultrasonography is utilized for small bowel imaging of IBD at some centers. The sensitivity and specificity are highly dependent on the experience of the operator but are reported to be between 76 and 92 percent [
         <a href="#rid54">
          54,79
         </a>
         ]. Sonographic features suggesting small bowel involvement include bowel wall thickening and stiffness, and changes in the bowel wall stratification, but intestinal gas frequently obscures the bowel wall [
         <a href="#rid80">
          80
         </a>
         ]. Superficial mucosal abnormalities are not detectable by ultrasound.
        </p>
        <p>
         Small intestine contrast ultrasonography (SICUS) is a technique in which an oral nonabsorbable anechoic contrast solution (eg,
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         ) is given by mouth prior to abdominal ultrasonography. One study in pediatric patients reported that SICUS had a sensitivity of 96 percent and specificity of 100 percent for detecting proximal or distal small bowel lesions, with excellent agreement with findings on UGI/SBFT [
         <a href="#rid81">
          81
         </a>
         ]. Like standard ultrasonography, SICUS is highly dependent on the experience of the operator. (See
         <a class="medical medical_review" href="/z/d/html/2565.html" rel="external">
          "Transabdominal ultrasonography of the small and large intestine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1679701079">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no specific diagnostic criteria for IBD. The diagnosis of IBD is usually established by the combination of clinical features, with or without laboratory abnormalities, coupled with characteristic findings on imaging and endoscopy, including histopathologic analysis. Endoscopy and imaging also help to exclude some other causes of the symptoms, and usually can distinguish between ulcerative colitis (UC) and Crohn disease (CD)  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H9479602">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Considerations in the differential diagnosis depend on dominant clinical features of an individual patient:
        </p>
        <p class="headingAnchor" id="H11173222">
         <span class="h2">
          Rectal bleeding
         </span>
        </p>
        <p>
         In children with rectal bleeding without diarrhea or other symptoms suggestive of IBD, causes of rectal bleeding other than IBD include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anal fissures or hemorrhoids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyps
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meckel's diverticulum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Milk protein-induced proctocolitis – Primarily seen in infants
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="medical medical_review" href="/z/d/html/5904.html" rel="external">
          "Lower gastrointestinal bleeding in children: Causes and diagnostic approach"
         </a>
         .)
        </p>
        <p>
         In children with rectal bleeding in combination with more complex symptoms, considerations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enteric pathogens
         </strong>
         – Infectious causes of intestinal inflammation that can mimic UC or CD include
         <em>
          Salmonella
         </em>
         ,
         <em>
          Shigella
         </em>
         ,
         <em>
          Yersinia
         </em>
         ,
         <em>
          Campylobacter
         </em>
         ,
         <em>
          Aeromonas
         </em>
         , enterohemorrhagic
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Amoeba
         </em>
         ,
         <em>
          Strongyloides
         </em>
         ,
         <em>
          Trichuris trichiura
         </em>
         , and
         <em>
          C. difficile
         </em>
         . In some cases, IBD can be triggered by an enteric infection, particularly
         <em>
          C. difficile
         </em>
         [
         <a href="#rid50">
          50,82
         </a>
         ]. Therefore, the presence of one of these pathogens does not exclude IBD. Moreover,
         <em>
          C. difficile
         </em>
         colonization is common, especially in young children, and it may be difficult to distinguish between colonization and infection in some cases [
         <a href="#rid51">
          51
         </a>
         ]. Patients whose rectal bleeding does not resolve after treatment for one of these pathogens should be reevaluated for IBD. (See
         <a class="medical medical_review" href="/z/d/html/6050.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in children: Treatment and outcome"
         </a>
         and
         <a class="local">
          'Stool testing for enteric pathogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cytomegalovirus (CMV) infection can cause colitis. In patients with IBD, superinfection with CMV is associated with a high rate of steroid resistance [
         <a href="#rid83">
          83
         </a>
         ]. Evaluation for CMV disease, using sigmoidoscopic biopsies, is suggested for patients with severe colitis that does not respond promptly to intravenous glucocorticoids (ie, steroid-refractory disease). (See
         <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">
          "Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intussusception
         </strong>
         – Characterized by acute onset of intermittent crampy abdominal pain, often with vomiting and lethargy, and sometimes progressing to rectal bleeding. (See
         <a class="medical medical_review" href="/z/d/html/5898.html" rel="external">
          "Intussusception in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoglobulin A vasculitis
         </strong>
         <strong>
          (IgAV)
         </strong>
         – IgAV, also known as Henoch-Schönlein purpura (HSP), also can cause rectal bleeding and abdominal pain. However, almost all patients with IgAV (HSP) also have characteristic purpuric skin lesions. (See
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Familial Mediterranean fever
         </strong>
         – Case reports describe apparent UC presenting in infants with genetic mutations of familial Mediterranean fever [
         <a href="#rid84">
          84
         </a>
         ]. Presenting symptoms included bloody diarrhea, failure to thrive, anemia and leukocytosis. These reports and epidemiologic studies in populations of adults suggest that the genes responsible for familial Mediterranean fever may have a disease-modifying effect on IBD [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">
          "Clinical manifestations and diagnosis of familial Mediterranean fever"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11173229">
         <span class="h2">
          Growth failure and diarrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children presenting with growth failure and/or nonbloody diarrhea should be evaluated for celiac disease. This can be done by serologic testing. (See
         <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11173236">
         <span class="h2">
          Abdominal pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with diffuse or poorly localized abdominal pain, the differential diagnosis includes functional gastrointestinal disease (including constipation and irritable bowel syndrome [IBS]), which is very common. IBD is generally distinguished from functional abdominal pain by the presence of additional symptoms (including diarrhea, rectal bleeding, and/or growth failure) and laboratory abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/111.html" rel="external">
          "Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Functional disorders'
         </a>
         .)
        </p>
        <p>
         Focal abdominal pain, particularly in the right lower quadrant, is more suspicious for IBD (particularly CD). For patients presenting with right lower quadrant pain, the differential diagnosis includes appendicitis and (very rarely) tuberculosis or lymphoma [
         <a href="#rid86">
          86
         </a>
         ]. In adolescent girls, gynecologic disease must be considered. In patients with an abdominal abscess, the differential diagnosis includes a perforated appendix, vasculitic perforation, or trauma. (See
         <a class="medical medical_review" href="/z/d/html/6454.html" rel="external">
          "Causes of acute abdominal pain in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11173243">
         <span class="h2">
          Extraintestinal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extraintestinal symptoms associated with IBD include arthritis, oral aphthae (superficial ulcerations, also known as aphthous stomatitis), skin disease (erythema nodosum and pyoderma gangrenosum), and episcleritis/iritis  (
         <a class="graphic graphic_table graphicRef81867" href="/z/d/graphic/81867.html" rel="external">
          table 1A
         </a>
         ). These manifestations rarely occur in the absence of gastrointestinal symptoms.
        </p>
        <p>
         Details about these manifestations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Extraintestinal manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3283441318">
         <span class="h1">
          VERY EARLY-ONSET INFLAMMATORY BOWEL DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         IBD that becomes symptomatic or is diagnosed before six years of age is termed "very early-onset IBD" (VEO-IBD). Compared with children whose IBD develops later in life, those with VEO-IBD, and particularly those with onset before two years of age (sometimes termed "infantile IBD"), are more likely to have monogenic IBD and often have a more severe disease course [
         <a href="#rid87">
          87,88
         </a>
         ]. The related gene defects cause an IBD-like disease by altering immune function or disturbing epithelial barrier function.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Clinical features that raise suspicion for monogenic IBD include  (
         <a class="graphic graphic_table graphicRef99327" href="/z/d/graphic/99327.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid6">
          6,9,89,90
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Young age of onset (eg, younger than six years, particularly younger than age two years)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of IBD and/or immunodeficiency in multiple family members, particularly with male predominance, or consanguinity
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent infections or unexplained fever
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Associated features of autoimmunity (eg, arthritis, sclerosing cholangitis, anemia, or endocrine dysfunction)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Very severe IBD, complex fistulizing disease, and/or resistance to conventional therapies for IBD
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms or signs suggesting hemophagocytic lymphohistiocytosis (hepatomegaly, fever, cytopenias, high ferritin) (see
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions of the skin, nails, or hair
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Current or past history of cancer in the patient
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endoscopic biopsies with tissue eosinophilia, villous flattening (without evidence of celiac disease)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes and evaluation
         </strong>
         – Infants or young children presenting with these features warrant careful evaluation for monogenic IBD and consultation with an immunologist  (
         <a class="graphic graphic_algorithm graphicRef99328" href="/z/d/graphic/99328.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid6">
          6,9,14
         </a>
         ]. Depending on individual patient features, the evaluation may include panel sequencing, exome sequencing, or genome sequencing technologies [
         <a href="#rid90">
          90
         </a>
         ]. Genetic sequencing is recommended for every child with IBD onset under age two years and also suggested for children under age six, particularly if other clinical features listed above are present, as outlined in a position paper from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Important causes of monogenic IBD include defects in interleukin-10 (IL-10) signaling, atypical severe combined immunodeficiency, common variable immunodeficiency, chronic granulomatous disease and other neutrophil defects, Wiskott-Aldrich syndrome, agammaglobulinemia, hyperimmunoglobulin M syndrome, familial hemophagocytic lymphohistiocytosis, and IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) or other autoimmune enteropathy  (
         <a class="graphic graphic_table graphicRef119229" href="/z/d/graphic/119229.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ] (see appropriate topic reviews).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details and an extensive list of genes that may be involved in VEO-IBD are provided in the ESPGHAN position paper [
         <a href="#rid90">
          90
         </a>
         ]. Some of these genes are now associated with well-described phenotypes (eg, TTC7A deficiency,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F243150&amp;token=tEpDslnpc0F0kICl%2Fz7sFZDxK7ki9TNJyVXNO7kDVoNNsiV4ENqkhYbjvE1pkc3b&amp;TOPIC_ID=5879" target="_blank">
          MIM #243150
         </a>
         ), while others have a phenotype that has yet to be extensively defined. (See
         <a class="medical medical_review" href="/z/d/html/4062.html" rel="external">
          "Genetic factors in inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116805.html" rel="external">
          "Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management approach
         </strong>
         – Identification of a specific monogenic immunologic disorder often requires different management strategies. Some of these mutations affect hematopoietic cells (eg,
         <em>
          IL10
         </em>
         ,
         <em>
          IL10RA
         </em>
         ,
         <em>
          XIAP
         </em>
         , and
         <em>
          FOXP3
         </em>
         ), and affected patients are candidates for hematopoietic stem cell transplantation. As an example, mutations in the
         <em>
          IL10RA
         </em>
         gene can present with severe intractable enterocolitis, perianal disease, folliculitis, and arthritis [
         <a href="#rid91">
          91
         </a>
         ]. For these very young patients, several gene sequencing panels are available [
         <a href="#rid92">
          92,93
         </a>
         ], and whole-exome or whole-genome sequencing is increasingly playing an important role in identifying novel genetic mutations and immune deficiencies [
         <a href="#rid94">
          94,95
         </a>
         ]. Other genetic syndromes, such as TTC7A deficiency, are not thought to be candidates for stem cell transplantation, but novel methods of drug screening may identify promising treatments for these life-threatening conditions [
         <a href="#rid96">
          96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99315.html" rel="external">
          "Gastrointestinal manifestations in primary immunodeficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9481834">
         <span class="h1">
          DIFFERENTIATION BETWEEN CROHN DISEASE AND ULCERATIVE COLITIS
         </span>
        </p>
        <p class="headingAnchor" id="H878205669">
         <span class="h2">
          Classification schemes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classification of the IBD facilitates clinical decisions, discussions with the family, eligibility for clinical trials, and epidemiologic research. If possible, the disease should be classified as either Crohn disease (CD) or ulcerative colitis (UC)  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ). This classification usually is accomplished with the combination of endoscopy and imaging of the small bowel. The provider should make every effort to classify the disease using standardized criteria. If the disease type remains uncertain after complete evaluation, it is provisionally termed IBD-unclassified (IBDU), formerly known as "indeterminate colitis" [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Guidelines for the classification of IBD in children were developed by a committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition [
         <a href="#rid30">
          30
         </a>
         ] and are summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef81966" href="/z/d/graphic/81966.html" rel="external">
          algorithm 2
         </a>
         ). More recently, the Pediatric IBD Porto Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition published the "PIBD-classes" criteria, a classification scheme that differentiates pediatric IBD into five diagnostic categories: typical UC, atypical UC, IBDU, Crohn colitis (colonic CD), and CD. This granular classification aims to assist the clinician in characterizing the degree of certainty as to whether a patient has CD, UC, or IBDU, based on typical and atypical clinical and laboratory features [
         <a href="#rid89">
          89,97,98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9480154">
         <span class="h2">
          Features of Crohn disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with IBD involving the colon, UC is distinguished from CD by a process of elimination.
        </p>
        <p>
         In a patient with IBD, any of the following features are
         <strong>
          diagnostic
         </strong>
         of CD  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination – Perianal fistulae, abscess, or large (&gt;5mm) skin tags  (
         <a class="graphic graphic_picture graphicRef121947" href="/z/d/graphic/121947.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging – Either magnetic resonance enterography (MRE)  (
         <a class="graphic graphic_diagnosticimage graphicRef117821" href="/z/d/graphic/117821.html" rel="external">
          image 1
         </a>
         ), upper gastrointestinal series with small bowel follow-through (UGI/SBFT), or computed tomography enterography (CTE) showing definitive small bowel involvement, with mucosal ulceration, cobblestoning, narrowing or obstruction, or enteric fistulae. Note that some magnetic resonance imaging or CT findings (eg "small bowel enhancement," or wall thickening) may be nonspecific "false positives." (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gross features at colonoscopy – Colonoscopic findings diagnostic of CD include ulceration and stenosis of the ileocecal valve, cobblestoning or linear ulcerations in the ileum, and stricture and fistula formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histopathologic features – Noncaseating granulomas  (
         <a class="graphic graphic_picture graphicRef60769" href="/z/d/graphic/60769.html" rel="external">
          picture 4
         </a>
         ) in a patient with IBD are diagnostic of CD, unless they are adjacent to ruptured crypts. However, mucosal biopsies reveal these lesions in only 25 to 50 percent of patients with CD [
         <a href="#rid30">
          30,99,100
         </a>
         ]. Transmural lymphoid aggregates are also diagnostic, but these can only be identified at colectomy. Although small bowel involvement is more likely in CD, gastritis or duodenitis may be present at the time of diagnosis in patients with either UC or CD [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In patients lacking the above diagnostic findings, CD should still be
         <strong>
          suspected
         </strong>
         if any of the following suggestive features are present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right lower quadrant mass
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging studies showing cecal narrowing, bowel rigidity, and bowel wall edema manifested by separation of bowel loops  (
         <a class="graphic graphic_diagnosticimage graphicRef71543" href="/z/d/graphic/71543.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Colonoscopic findings of small ulcers (aphthous lesions) in the colon or discontinuous colitis with intervening areas of normal mucosa ("skip areas")  (
         <a class="graphic graphic_picture graphicRef78561 graphicRef68093 graphicRef71769" href="/z/d/graphic/78561.html" rel="external">
          picture 5A-C
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Patients with these suggestive features but no diagnostic findings of CD should be provisionally classified as either CD or IBDU, and the suspicious features should be followed closely over time in an effort to establish a definitive diagnosis of CD or UC.
        </p>
        <p>
         Although UGI tract involvement is a feature of CD but not UC, the finding of a nonspecific gastritis on upper endoscopy does not help to distinguish the two disorders. This was shown in a prospective study in a cohort of patients with CD or UC who underwent upper endoscopy [
         <a href="#rid101">
          101
         </a>
         ]. Both groups had endoscopic and histologic features of gastritis (92 versus 69 percent in CD versus UC, respectively) and duodenitis (33 versus 23 percent in CD versus UC, respectively).
        </p>
        <p class="headingAnchor" id="H9480161">
         <span class="h2">
          Features of ulcerative colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In UC, typical findings on colonoscopy include a diffuse, continuous process starting at the rectum and extending more proximally into the colon  (
         <a class="graphic graphic_picture graphicRef76332" href="/z/d/graphic/76332.html" rel="external">
          picture 6
         </a>
         ). Active disease is characterized by diffuse and continuous edema, erythema, induced and spontaneous friability, and ulceration. The distal colon is usually more severely involved than more proximal aspects of the colon. In severe, relatively acute disease, extensive erosions and ulcerations may be present. Patients with longer-standing disease may have "pseudopolyps," which are islands of regenerating mucosa that appear polypoid, surrounded by relatively atrophic tissue.
        </p>
        <p>
         The histopathological features of UC include mucosal and submucosal inflammation, cryptitis, and crypt abscess formation; distortion of the architecture; basal lymphoid aggregates; and the presence of Paneth cells in the left colon. The last three features listed suggest chronicity, which if present helps to distinguish the disease from an infectious colitis, which tends to be acute. The inflammation is typically diffuse, compared with the patchy patterns often observed in patients with CD. However, early in the course of pediatric ulcerative colitis, atypical histologic features may be seen, including patchy disease and relative rectal sparing [
         <a href="#rid30">
          30,102
         </a>
         ].
        </p>
        <p>
         The following clinical features are not typical of UC, so they are sometimes called "nonclassic" features. They are found with sufficient frequency in patients with UC that they do not necessarily exclude that diagnosis [
         <a href="#rid30">
          30,102
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small anal fissures and skin tags; oral ulcers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gross or histologic evidence of gastritis (without aphthae)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Backwash" ileitis, defined as ileal erythema or histologic inflammation (but no linear ulceration or granuloma) [
         <a href="#rid103">
          103
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periappendiceal inflammation, even in a patient without pancolitis ("cecal patch")  (
         <a class="graphic graphic_picture graphicRef53637" href="/z/d/graphic/53637.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid104">
          104
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rectal inflammation that is less severe than in the more proximal colon (relative rectal sparing)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patchy distribution of colitis (histopathologically normal colonic mucosa between two areas of colonic inflammation)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9480168">
         <span class="h2">
          Antibody testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibody testing has limited utility for discriminating between UC and CD, and practice guidelines for children and adults are equivocal regarding its use [
         <a href="#rid30">
          30,89,105
         </a>
         ]. The most common antibody tests are perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) and anti-saccharomyces cerevisiae antibodies (ASCA) [
         <a href="#rid106">
          106-108
         </a>
         ]. When combined into panels, the antibody tests have reasonably high sensitivities for detecting IBD (&gt;90 percent in populations with symptoms), but their ability to distinguish between UC and CD is not well validated [
         <a href="#rid109">
          109-112
         </a>
         ]. The sensitivity and specificity of P-ANCA and ASCA tests are similar in adults and children with IBD [
         <a href="#rid106">
          106-108,113
         </a>
         ].
        </p>
        <p>
         The positive predictive value (PPV) of these tests depends on the prior likelihood of disease. Patients with low levels of symptoms, or patients from populations with a low incidence of IBD, are more likely to have false-positive results [
         <a href="#rid110">
          110
         </a>
         ]. The tests have greater PPV for patients with higher levels of symptoms, but in most cases, these symptoms would be sufficient indication for proceeding with an endoscopic evaluation. Thus, antibody testing for IBD does not generally contribute useful information to management decisions.
        </p>
        <p>
         A positive ASCA test is weakly associated with CD, and positive P-ANCA is weakly associated with UC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ASCA antibodies are found in 40 to 80 percent of individuals with CD, tend to identify patients with disease of the terminal ileum and cecum, and are unusual in patients with UC [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         P-ANCA can be detected in 50 to 80 percent of children and adults with ulcerative colitis compared with 10 to 27 percent of adults with CD (in whom only low titers may be present) [
         <a href="#rid106">
          106,114-116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with CD who have P-ANCA antibodies often exhibit UC-like features, with disease limited to the colon. Thus, the serotype may be more closely associated with colonic disease location than with disease type [
         <a href="#rid30">
          30,114,117,118
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The anti-OmpC antibody has been identified as a potential serologic marker of IBD [
         <a href="#rid119">
          119
         </a>
         ]. The OmpC is an outer membrane porin,
         <em>
          E. coli
         </em>
         protein that is immunoreactive to P-ANCA monoclonal antibodies [
         <a href="#rid120">
          120
         </a>
         ]. In a study of 198 children, anti-OmpC was detected in 25 percent of patients with CD (n = 81), 11 percent of patients with UC (n = 54), and 5 percent of controls (n = 63) [
         <a href="#rid108">
          108
         </a>
         ]. Because anti-OmpC was positive in nine children with IBD who were not detected by ASCA (IgA and IgG) or P-ANCA, the addition of anti-OmpC to these antibody assays increased the sensitivity from 63 to 70 percent but decreased the specificity from 97 to 94 percent.
        </p>
        <p>
         Antibodies to the bacterial flagellin CBir1 are found in approximately 50 percent of individuals with CD and have been associated with small bowel, internal-penetrating, and fibrostenosing patterns [
         <a href="#rid110">
          110,121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          LOCALIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The location of the disease should be determined as accurately as possible, based on a combination of imaging, endoscopic, and histopathologic results. These studies should optimally be performed before significant therapy since this may alter the findings. The location, severity, and other important characteristics are classified using the Paris classification system, which was developed specifically for clinical studies involving pediatric patients with ulcerative colitis (UC) or Crohn disease (CD) [
         <a href="#rid122">
          122
         </a>
         ]. For UC, the disease involvement should be categorized as proctitis (rectal involvement limited to 15 cm or less), left-sided colitis, extensive colitis (extending past the splenic flexure), or pancolitis (extending past the hepatic flexure)  (
         <a class="graphic graphic_table graphicRef89029" href="/z/d/graphic/89029.html" rel="external">
          table 6
         </a>
         ). For CD, localizing disease means identifying whether the mouth, esophagus, stomach, small bowel, colon, or anus are involved  (
         <a class="graphic graphic_figure graphicRef89025" href="/z/d/graphic/89025.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_table graphicRef89028" href="/z/d/graphic/89028.html" rel="external">
          table 7
         </a>
         ). By defining the affected areas of the gastrointestinal tract, the clinician will be able to better target medical management appropriately.
        </p>
        <p class="headingAnchor" id="H1693958240">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">
          "Society guideline links: Inflammatory bowel disease in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361154165">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/86454.html" rel="external">
          "Patient education: Crohn disease in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86458.html" rel="external">
          "Patient education: Ulcerative colitis in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1991.html" rel="external">
          "Patient education: Ulcerative colitis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2004.html" rel="external">
          "Patient education: Crohn disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Typical presenting features of inflammatory bowel disease (IBD) in children are loose stools or bloody diarrhea, abdominal pain, fever, weight loss or growth failure, perianal disease, anemia, arthritis, or delayed onset of puberty  (
         <a class="graphic graphic_table graphicRef77827" href="/z/d/graphic/77827.html" rel="external">
          table 2
         </a>
         ). Clinical features supportive of the diagnosis include abdominal tenderness, oral ulcers, or perianal disease. (See
         <a class="local">
          'Typical presenting symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory features
         </strong>
         – Laboratory testing often reveals anemia, hypoalbuminemia, and/or an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP); however, laboratory studies are normal in a significant number of children with IBD. (See
         <a class="local">
          'Laboratory features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – If the clinical presentation and/or initial laboratory testing support the diagnosis of IBD, further evaluation should include small bowel imaging and colonoscopy (with biopsies taken from the terminal ileum, if possible). Biopsies from the terminal ileum and each segment of the colon should be sent for histopathologic examination. In many centers, upper endoscopy is also routinely performed at the time of the initial colonoscopy and provides further information as to disease type and extent  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid123">
          123
         </a>
         ]. (See
         <a class="local">
          'Endoscopy'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children who present with IBD before six years of age, especially those younger than two years or with any features of monogenic IBD  (
         <a class="graphic graphic_table graphicRef99327" href="/z/d/graphic/99327.html" rel="external">
          table 4
         </a>
         ), should be carefully evaluated for monogenic IBD, including immunologic evaluation and genetic sequencing. (See
         <a class="local">
          'Very early-onset inflammatory bowel disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – In patients presenting with rectal bleeding, laboratory testing should be performed to exclude other illnesses, including stool cultures and C. difficile toxin. If stools are formed (ie, not diarrhea), other causes of rectal bleeding should be explored, including Meckel's diverticulum, polyps, and anal fissures. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Crohn disease (CD) versus ulcerative colitis (UC)
         </strong>
         – In patients with colitis, imaging and endoscopy also are used to differentiate between UC and CD  (
         <a class="graphic graphic_algorithm graphicRef81966" href="/z/d/graphic/81966.html" rel="external">
          algorithm 2
         </a>
         ). Features diagnostic of CD include evidence of small bowel involvement on advanced imaging  (
         <a class="graphic graphic_diagnosticimage graphicRef117821" href="/z/d/graphic/117821.html" rel="external">
          image 1
         </a>
         ); noncaseating granulomas on histopathologic examination; and/or marked perianal disease  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Differentiation between Crohn disease and ulcerative colitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extraintestinal manifestations
         </strong>
         – Extraintestinal manifestations of IBD may involve the skin, mouth, joints, liver, eye, bones, and (rarely) other organs  (
         <a class="graphic graphic_table graphicRef81867" href="/z/d/graphic/81867.html" rel="external">
          table 1A
         </a>
         ). Patients with suspected or confirmed IBD should be screened for these disorders by a focused history and physical examination. (See
         <a class="local">
          'Extraintestinal manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most serious liver disease associated with IBD is sclerosing cholangitis, a progressive liver disease that may be complicated by cirrhosis and hepatobiliary cancer. Patients with IBD should undergo laboratory screening for hepatobiliary disease at diagnosis and periodically thereafter. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Sclerosing cholangitis'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis 2008; 14 Suppl 2:S4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013; 58:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghione S, Sarter H, Fumery M, et al. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents. Am J Gastroenterol 2018; 113:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess CJ, Henderson P, Jones GR, et al. Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases. J Pediatr Gastroenterol Nutr 2020; 71:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gryboski JD. Ulcerative colitis in children 10 years old or younger. J Pediatr Gastroenterol Nutr 1993; 17:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mamula P, Telega GW, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002; 97:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsen JR, Sullivan KE, Rabizadeh S, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020; 70:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan GG, Bernstein CN, Coward S, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. J Can Assoc Gastroenterol 2019; 2:S6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008; 40:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouahed J, Spencer E, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis 2020; 26:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandrakumar A, Wang A, Grover K, El-Matary W. Obesity Is More Common in Children Newly Diagnosed With Ulcerative Colitis as Compared to Those With Crohn Disease. J Pediatr Gastroenterol Nutr 2020; 70:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aloi M, Lionetti P, Barabino A, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014; 20:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliva-Hemker M, Hutfless S, Al Kazzi ES, et al. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr 2015; 167:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gryboski JD. Crohn's disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 18:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbraith SS, Drolet BA, Kugathasan S, et al. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 2005; 116:e439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007; 119:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aljomah G, Baker SS, Schmidt K, et al. Anemia in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2018; 67:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaoul R, Sladek M, Turner D, et al. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, Berger MY. Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America, Bousvaros A, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtman GA, Lisman-van Leeuwen Y, Day AS, et al. Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data. JAMA Pediatr 2017; 171:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van de Vijver E, Schreuder AB, Cnossen WR, et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 2012; 97:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heida A, Holtman GA, Lisman-van Leeuwen Y, et al. Avoid Endoscopy in Children With Suspected Inflammatory Bowel Disease Who Have Normal Calprotectin Levels. J Pediatr Gastroenterol Nutr 2016; 62:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, et al. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study. Ann Fam Med 2016; 14:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker GJ, Chanchlani N, Thomas A, et al. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child 2020; 105:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olafsdottir I, Nemeth A, Lörinc E, et al. Value of Fecal Calprotectin as a Biomarker for Juvenile Polyps in Children Investigated With Colonoscopy. J Pediatr Gastroenterol Nutr 2016; 62:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright EK, De Cruz P, Gearry R, et al. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis 2014; 20:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140:1817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011; 56:2372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou XL, Xu W, Tang XX, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol 2014; 14:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stragier E, Van Assche G. The use of fecal calprotectin and lactoferrin in patients with IBD. Review. Acta Gastroenterol Belg 2013; 76:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van de Vijver E, Heida A, Ioannou S, et al. Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir SA, Kellermayer R. Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States. J Pediatr Gastroenterol Nutr 2013; 57:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellermayer R. Burdening questions about Clostridium difficile in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 2015; 60:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliva S, Thomson M, de Ridder L, et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thakkar K, El-Serag HB, Mattek N, Gilger M. Complications of pediatric colonoscopy: a five-year multicenter experience. Clin Gastroenterol Hepatol 2008; 6:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltz R, Podberesky DJ, Saeed SA. Imaging modalities in pediatric inflammatory bowel disease. Curr Opin Pediatr 2014; 26:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenup AJ, Bressler B, Rosenfeld G. Medical Imaging in Small Bowel Crohn's Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: "Which One Is the Best for What?". Inflamm Bowel Dis 2016; 22:1246.
          </a>
         </li>
         <li class="breakAll">
          American College of Radiology. ACR Appropriateness Criteria: Crohn Disease-Child. 2021. Available at: https://acsearch.acr.org/docs/3158174/Narrative/ (Accessed on June 01, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JS, Tobin A, Harvey L, Nelson TR. Diagnostic medical radiation in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon HM, Suh CH, Kim JR, et al. Diagnostic Performance of Magnetic Resonance Enterography for Detection of Active Inflammation in Children and Adolescents With Inflammatory Bowel Disease: A Systematic Review and Diagnostic Meta-analysis. JAMA Pediatr 2017; 171:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles E, Hanci O, McLean A, et al. Optimal assessment of paediatric IBD with MRI and barium follow-through. J Pediatr Gastroenterol Nutr 2012; 54:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bie CI, Buderus S, Sandhu BK, et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr 2012; 54:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mojtahed A, Gee MS. Magnetic resonance enterography evaluation of Crohn disease activity and mucosal healing in young patients. Pediatr Radiol 2018; 48:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gee MS, Nimkin K, Hsu M, et al. Prospective evaluation of MR enterography as the primary imaging modality for pediatric Crohn disease assessment. AJR Am J Roentgenol 2011; 197:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courtier J, Cardenas A, Tan C, et al. Non-Anesthesia MR Enterography in Very Young Children-Feasibility, Technique and Performance. J Pediatr Gastroenterol Nutr 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfefferkorn MD, Marshalleck FE, Saeed SA, et al. NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula. J Pediatr Gastroenterol Nutr 2013; 57:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillman JR, Adler J, Zimmermann EM, Strouse PJ. CT enterography of pediatric Crohn disease. Pediatr Radiol 2010; 40:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid JR, Pozzuto J, Morrison S, et al. Comparison of gonadal radiation doses from CT enterography and small-bowel follow-through in pediatric patients. AJR Am J Roentgenol 2015; 204:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaca AM, Jaffe TA, Delaney S, et al. Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatr Radiol 2008; 38:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008; 57:1524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hara AK, Leighton JA, Heigh RI, et al. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology 2006; 238:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedlander JA, Liu QY, Sahn B, et al. NASPGHAN Capsule Endoscopy Clinical Report. J Pediatr Gastroenterol Nutr 2017; 64:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atay O, Mahajan L, Kay M, et al. Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature. J Pediatr Gastroenterol Nutr 2009; 49:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen MK, Tipnis NA, Bajorunaite R, et al. Capsule endoscopy performed across the pediatric age range: indications, incomplete studies, and utility in management of inflammatory bowel disease. Gastrointest Endosc 2010; 72:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gralnek IM, Cohen SA, Ephrath H, et al. Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci 2012; 57:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Min SB, Le-Carlson M, Singh N, et al. Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis 2013; 19:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemeth A, Agardh D, Wurm Johansson G, et al. Video capsule endoscopy in pediatric patients with Crohn's disease: a single-center experience of 180 procedures. Therap Adv Gastroenterol 2018; 11:1756284818758929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson M, Fritscher-Ravens A, Mylonaki M, et al. Wireless capsule endoscopy in children: a study to assess diagnostic yield in small bowel disease in paediatric patients. J Pediatr Gastroenterol Nutr 2007; 44:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen SA, Klevens AI. Use of capsule endoscopy in diagnosis and management of pediatric patients, based on meta-analysis. Clin Gastroenterol Hepatol 2011; 9:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enns RA, Hookey L, Armstrong D, et al. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology 2017; 152:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsthuis K, Stokkers PC, Stoker J. Detection of inflammatory bowel disease: diagnostic performance of cross-sectional imaging modalities. Abdom Imaging 2008; 33:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Civitelli F, Di Nardo G, Oliva S, et al. Ultrasonography of the colon in pediatric ulcerative colitis: a prospective, blind, comparative study with colonoscopy. J Pediatr 2014; 165:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pallotta N, Civitelli F, Di Nardo G, et al. Small intestine contrast ultrasonography in pediatric Crohn's disease. J Pediatr 2013; 163:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, et al. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis 2012; 18:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis 2009; 3:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sari S, Egritas O, Dalgic B. The familial Mediterranean fever (MEFV) gene may be a modifier factor of inflammatory bowel disease in infancy. Eur J Pediatr 2008; 167:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000; 355:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh SK, Srivastava A, Kumari N, et al. Differentiation Between Crohn Disease and Intestinal Tuberculosis in Children. J Pediatr Gastroenterol Nutr 2018; 66:e6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsen JR, Conrad MA, Dawany N, et al. The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease. Inflamm Bowel Dis 2020; 26:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerur B, Benchimol EI, Fiedler K, et al. Natural History of  Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study. Inflamm Bowel Dis 2021; 27:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhlig HH, Charbit-Henrion F, Kotlarz D, et al. Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2021; 72:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kammermeier J, Dziubak R, Pescarin M, et al. Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years. J Crohns Colitis 2017; 11:60.
          </a>
         </li>
         <li class="breakAll">
          Emory Genetics Laboratory. Early Onset Inflammatory Bowel Disease: Sequencing Panel. Available at: http://geneticslab.emory.edu/tests/MM160 (Accessed on December 05, 2016).
         </li>
         <li class="breakAll">
          GeneTests, a medical genetics information resource. Available at: https://www.genetests.org/tests/ (Accessed on December 05, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsen JR, Dawany N, Moran CJ, et al. Exome sequencing analysis reveals variants in primary immunodeficiency genes in patients with very early onset inflammatory bowel disease. Gastroenterology 2015; 149:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CJ, Klein C, Muise AM, Snapper SB. Very early-onset inflammatory bowel disease: gaining insight through focused discovery. Inflamm Bowel Dis 2015; 21:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardine S, Anderson S, Babcock S, et al. Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Disease Caused by TTC7A Deficiency. Gastroenterology 2020; 158:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birimberg-Schwartz L, Zucker DM, Akriv A, et al. Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN. J Crohns Colitis 2017; 11:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruuska T, Vaajalahti P, Arajärvi P, Mäki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 1994; 19:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Matos V, Russo PA, Cohen AB, et al. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 46:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin JM, Sinha B, Ramani P, et al. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. J Pediatr Gastroenterol Nutr 2001; 32:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 2013; 19:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Najarian RM, Ashworth LA, Wang HH, et al. Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2019; 68:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strisciuglio C, Giannetti E, Giugliano FP, et al. Periappendiceal inflammation in pediatric ulcerative colitis. Inflamm Bowel Dis 2013; 19:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001; 96:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007; 119:e193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics 2010; 125:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birimberg-Schwartz L, Wilson DC, Kolho KL, et al. pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHAN. Inflamm Bowel Dis 2016; 22:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger TD, Lee HM, Padmanaban LR, et al. Clinical Features and Outcomes of Paediatric Patients With Isolated Colonic Crohn Disease. J Pediatr Gastroenterol Nutr 2022; 74:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winter HS, Landers CJ, Winkelstein A, et al. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994; 125:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutgeerts P, Vermeire S. Serological diagnosis of inflammatory bowel disease. Lancet 2000; 356:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura RM, Barry M. Serologic markers in inflammatory bowel disease (IBD). MLO Med Lab Obs 2001; 33:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5879 Version 66.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18816745" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : What is the peak age for onset of IBD?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22926499" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28809388" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32639452" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15644819" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058236" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The diagnostic approach to monogenic very early onset inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8350209" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ulcerative colitis in children 10 years old or younger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12190168" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Inflammatory bowel disease in children 5 years of age and younger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32079889" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31294381" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18725221" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18692056" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Natural history of pediatric Crohn's disease: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18758464" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31833544" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17961699" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31977953" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Obesity Is More Common in Children Newly Diagnosed With Ulcerative Colitis as Compared to Those With Crohn Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24569242" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Phenotype and disease course of early-onset pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25982142" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8014764" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Crohn's disease in children 10 years old and younger: comparison with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3181677" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18626963" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20453677" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16099852" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545378" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Laboratory values for children with newly diagnosed inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29668567" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Anemia in Pediatric Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492204" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Indications for investigation of chronic gastrointestinal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370604" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22275268" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26681783" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460505" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14571234" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20634346" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23670113" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806445" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23019289" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26252922" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Avoid Endoscopy in Children With Suspected Inflammatory Bowel Disease Who Have Normal Calprotectin Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27621160" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32424002" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26147630" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Value of Fecal Calprotectin as a Biomarker for Juvenile Polyps in Children Investigated With Colonoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918319" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Fecal biomarkers in the diagnosis and monitoring of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12818275" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18484671" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21530748" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22344983" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21394462" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25002150" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24261027" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32694147" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22773060" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23783013" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25658059" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Burdening questions about Clostridium difficile in pediatric inflammatory bowel diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30130311" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18356115" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Complications of pediatric colonoscopy: a five-year multicenter experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25029227" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Imaging modalities in pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27070909" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Medical Imaging in Small Bowel Crohn's Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: "Which One Is the Best for What?".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27070909" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Medical Imaging in Small Bowel Crohn's Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: "Which One Is the Best for What?".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22020539" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diagnostic medical radiation in pediatric patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29052734" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Diagnostic Performance of Magnetic Resonance Enterography for Detection of Active Inflammation in Children and Adolescents With Inflammatory Bowel Disease: A Systematic Review and Diagnostic Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22588598" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Optimal assessment of paediatric IBD with MRI and barium follow-through.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21857248" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30078049" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Magnetic resonance enterography evaluation of Crohn disease activity and mucosal healing in young patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21701034" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prospective evaluation of MR enterography as the primary imaging modality for pediatric Crohn disease assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25564800" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Non-Anesthesia MR Enterography in Very Young Children-Feasibility, Technique and Performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23783018" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19936733" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : CT enterography of pediatric Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25714293" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Comparison of gonadal radiation doses from CT enterography and small-bowel follow-through in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18183380" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18443021" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Crohn's disease: factors associated with exposure to high levels of diagnostic radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16373764" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27642781" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : NASPGHAN Capsule Endoscopy Clinical Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19561547" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20472231" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Capsule endoscopy performed across the pediatric age range: indications, incomplete studies, and utility in management of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21901253" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23867872" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29531578" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Video capsule endoscopy in pediatric patients with Crohn's disease: a single-center experience of 180 procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255830" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Wireless capsule endoscopy in children: a study to assess diagnostic yield in small bowel disease in paediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21440674" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Use of capsule endoscopy in diagnosis and management of pediatric patients, based on meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28063287" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Clinical Practice Guidelines for the Use of Video Capsule Endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17619923" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Detection of inflammatory bowel disease: diagnostic performance of cross-sectional imaging modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24725581" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Ultrasonography of the colon in pediatric ulcerative colitis: a prospective, blind, comparative study with colonoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623514" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Small intestine contrast ultrasonography in pediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21936029" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21172262" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The role of CMV in steroid-resistant ulcerative colitis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520284" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The familial Mediterranean fever (MEFV) gene may be a modifier factor of inflammatory bowel disease in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665562" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28489674" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Differentiation Between Crohn Disease and Intestinal Tuberculosis in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31560377" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32386060" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Natural History of Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231644" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33346580" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27302973" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27302973" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27302973" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26193622" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Exome sequencing analysis reveals variants in primary immunodeficiency genes in patients with very early onset inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25895007" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Very early-onset inflammatory bowel disease: gaining insight through focused discovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31743734" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Disease Caused by TTC7A Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28430891" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30044357" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7815240" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18367950" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Frequency and clinical correlations of granulomas in children with Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11396811" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22570259" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31124991" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23552766" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Periappendiceal inflammation in pediatric ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20068560" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753483" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11280547" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15555007" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17158948" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17433787" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A critical evaluation of serologic markers for inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20439597" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Shortcomings of the inflammatory bowel disease Serology 7 panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27135480" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHAN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9691915" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34694270" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Clinical Features and Outcomes of Paediatric Patients With Isolated Colonic Crohn Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7965422" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930366" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11191535" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Serological diagnosis of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984510" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The value of serologic markers in indeterminate colitis: a prospective follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11721286" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Serologic markers in inflammatory bowel disease (IBD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678972" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Colonic bacteria express an ulcerative colitis pANCA-related protein epitope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17260364" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21560194" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15990620" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
